School of Medicine
Showing 1-100 of 650 Results
Assistant Professor of Chemical Engineering and of Genetics
Current Research and Scholarly InterestsWe study the role of the lysosome in metabolic adaptation using subcellular omics approaches, functional genomics and innovative biochemical tools. We apply this knowledge to understand how lysosomal dysfunction leads to human diseases including neurodegeneration, cancer and metabolic syndrome.
Alyce Sophia Adams
Stanford Medicine Innovation Professor and Professor of Epidemiology and Population Health, of Health Policy and, by courtesy, of Pediatrics (Endocrinology)
BioDr. Adams is the inaugural Stanford Medicine Innovation Professor and Professor of Health Policy, Epidemiology and Population Health and of Pediatrics (by Courtesy). She also serves as Associate Chair for Health Equity and Community Engagement for Stanford Health Policy, Associate Director for Health Equity and Community Engagement in the Stanford Cancer Institute, and as Associate Director for Stanford Impact Labs. Focusing on racial and socioeconomic disparities in chronic disease treatment outcomes, Dr. Adams' interdisciplinary research seeks to evaluate the impact of changes in drug coverage policy on access to essential medications, understand the drivers of disparities in treatment adherence among insured populations, and test strategies for maximizing the benefits of treatment outcomes while minimizing harms through informed decision-making. Prior to joining Stanford School of Medicine, Dr. Adams was Associate Director for Health Care Delivery and Policy and a Research Scientist at the Kaiser Permanente Division of Research, as well as a Professor at the Bernard J. Tyson Kaiser Permanente School of Medicine. From 2000 to 2008, she was an Assistant Professor in the Department of Population Medicine (formerly Ambulatory Care and Prevention) at Harvard Medical School and Harvard Pilgrim Health Care. She received her PhD in Health Policy and an MPP in Social Policy from Harvard University. She is a member of the Board of Directors for AcademyHealth and a former recipient of the John M. Eisenberg Excellence in Mentoring Award from Agency for Healthcare Research and Quality.
Saul A. Rosenberg, MD, Professor of Lymphoma
Current Research and Scholarly InterestsClinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.
Clinical Associate Professor, Pediatrics - Hematology & Oncology
Current Research and Scholarly InterestsI conduct clinical research on the prevention, early diagnosis, and treatment of infectious complications in pediatric patients with leukemia.
Professor of Pediatrics (Stem Cell Transplantation)
Current Research and Scholarly InterestsHematopoietic Stem cell biology-created a SCID mouse model to study engraftment of cord blood derived hematopoietic cells and use of this model to develop gene transfer technology for Fanconi anemia.
Clinical research interests are to develop new protocols to reduce Toxicity from the conditioning regimens for stem cell transplants, reducing graft vs host disease, treatment of viral infections post transplant and use of manipulated HSC graft in patients who receive haplo donor transplants.
Ash A. Alizadeh, MD/PhD
Moghadam Family Professor
Current Research and Scholarly InterestsMy research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.
Professor of Pathology
Current Research and Scholarly InterestsDr. Allisons clinical expertise is in breast pathology. Her research interests include how standards should be applied to breast cancer diagnostics (such as ER and HER2 testing), the utility of molecular panel-based testing in breast cancer, digital pathology applications and identifying the most appropriate management of specific pathologic diagnoses.
Russ B. Altman
Kenneth Fong Professor and Professor of Bioengineering, of Genetics, of Medicine, of Biomedical Data Science, Senior Fellow at the Stanford Institute for HAI and Professor, by courtesy, of Computer Science
Current Research and Scholarly InterestsI refer you to my web page for detailed list of interests, projects and publications. In addition to pressing the link here, you can search "Russ Altman" on http://www.google.com/
Associate Professor of Pathology
BioMichael Angelo, MD PhD is a board-certified pathologist and assistant professor in the department of Pathology at Stanford University School of Medicine. Dr. Angelo is a leader in high dimensional imaging with expertise in tissue homeostasis, tumor immunology, and infectious disease. His lab has pioneered the construction and development of Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF). MIBI-TOF uses secondary ion mass spectrometry and metal-tagged antibodies to achieve rapid, simultaneous imaging of dozens of proteins at subcellular resolution. In recognition of this achievement, Dr. Angelo received the NIH Director’s Early Independence award in 2014. His lab has since used this novel technology to discover previously unknown rule sets governing the spatial organization and cellular composition of immune, stromal, and tumor cells within the tumor microenvironment in triple negative breast cancer. These findings were found to be predictive of single cell expression of several immunotherapy drug targets and of 10-year overall survival. This effort has led to ongoing work aimed at elucidating structural mechanisms in the TME that promote recruitment of cancer associated fibroblasts, tumor associated macrophages, and extracellular matrix remodeling. Dr. Angelo is the recipient of the 2020 DOD Era of Hope Award and a principal investigator on multiple extramural awards from the National Cancer Institute, Breast Cancer Research Foundation, Parker Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, and the Human Biomolecular Atlas (HuBMAP) initiative.
Justin P. Annes M.D., Ph.D.
Associate Professor of Medicine (Endocrinology)
Current Research and Scholarly InterestsThe ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders
The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.
(1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.
(2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.
HEREDIATY PARAGAGLIOMA SYNDROME
The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.
As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.
Associate Professor of Materials Science and Engineering, Senior Fellow at the Woods Institute for the Environment and Associate Professor, by courtesy, of Pediatrics (Endocrinology)
Current Research and Scholarly InterestsThe underlying theme of the Appel Lab at Stanford University integrates concepts and approaches from supramolecular chemistry, natural/synthetic materials, and biology. We aim to develop supramolecular biomaterials that exploit a diverse design toolbox and take advantage of the beautiful synergism between physical properties, aesthetics, and low energy consumption typical of natural systems. Our vision is to use these materials to solve fundamental biological questions and to engineer advanced healthcare solutions.
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsResearch interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.
Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry
Current Research and Scholarly InterestsTelomeres are nucleoprotein complexes that protect chromosome ends and shorten with cell division and aging. We are interested in how telomere shortening influences cancer, stem cell function, aging and human disease. Telomerase is a reverse transcriptase that synthesizes telomere repeats and is expressed in stem cells and in cancer. We have found that telomerase also regulates stem cells and we are pursuing the function of telomerase through diverse genetic and biochemical approaches.
Ann M. Arvin
Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology and Immunology, Emerita
Current Research and Scholarly InterestsOur laboratory investigates the pathogenesis of varicella zoster virus (VZV) infection, focusing on the functional roles of particular viral gene products in pathogenesis and virus-cell interactions in differentiated human cells in humans and in Scid-hu mouse models of VZV cell tropisms in vivo, and the immunobiology of VZV infections.
Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics
Current Research and Scholarly InterestsOur research is aimed at defining the pathways of p53-mediated apoptosis and tumor suppression, using a combination of biochemical, cell biological, and mouse genetic approaches. Our strategy is to start by generating hypotheses about p53 mechanisms of action using primary mouse embryo fibroblasts (MEFs), and then to test them using gene targeting technology in the mouse.
Professor of Pathology
Current Research and Scholarly InterestsGenetic and cell biological analyses of signals controlling cell polarity and morphogenesis. Frizzled signaling and cytoskeletal organization.
Professor of Cardiothoracic Surgery (Thoracic Surgery)
BioLeah Backhus trained in general surgery at the University of Southern California and cardiothoracic surgery at the University of California Los Angeles. She practices at Stanford Hospital and is Chief of Thoracic Surgery at the VA Palo Alto. Her surgical practice consists of general thoracic surgery with special emphasis on thoracic oncology and minimally invasive surgical techniques. She is also Co-Director of the Thoracic Surgery Clinical Research Program, and has grant funding through the Veterans Affairs Administration and NIH. Her current research interests are in imaging surveillance following treatment for lung cancer and cancer survivorship. She is a member of the National Lung Cancer Roundtable of the American Cancer Society serving as Chair of the Task Group on Lung Cancer in Women. She also serves on the Board of Directors of the Society of Thoracic Surgeons. As an educator, Dr. Backhus is the Associate Program Director for the Thoracic Track Residency and is the Chair of the ACGME Residency Review Committee for Thoracic Surgery which is the accrediting body for all cardiothoracic surgery training programs in the US.
Annelise E. Barron
Associate Professor of Bioengineering
Current Research and Scholarly InterestsBiophysical mechanisms of host defense peptides (a.k.a. antimicrobial peptides) and their peptoid mimics; also, molecular and cellular biophysics of human innate immune responses.
Associate Professor of Genetics
Current Research and Scholarly InterestsWe are an interdisciplinary lab focused on two major areas:(1) we seek to understand mechanisms of cancer growth and drug resistance in order to find new therapeutic targets(2) we study mechanisms by which macrophages and other cells take up diverse materials by endocytosis and phagocytosis; these substrates range from bacteria, viruses, and cancer cells to drugs and protein toxins. To accomplish these goals, we develop and use new technologies for high-throughput functional genomics.
The Ernest and Amelia Gallo Professor, Professor of Urology, of Developmental Biology and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsFunction of Hedgehog proteins and other extracellular signals in morphogenesis (pattern formation), in injury repair and regeneration (pattern maintenance). We study how the distribution of such signals is regulated in tissues, how cells perceive and respond to distinct concentrations of signals, and how such signaling pathways arose in evolution. We also study the normal roles of such signals in stem-cell physiology and their abnormal roles in the formation and expansion of cancer stem cells.
Christopher Beaulieu M.D., Ph.D.
Professor of Radiology (Musculoskeletal Imaging) and, by courtesy, of Orthopaedic Surgery
Current Research and Scholarly InterestsInformatics and image processing techniques that provide infrastructure for diagnosis in musculoskeletal imaging. Decision support for improving accuracy of bone tumor diagnosis. Improved methods for MRI in the musculoskeletal system.
Hans-Christoph Becker, MD, FSABI, FSCCT
Clinical Professor, Radiology
Current Research and Scholarly InterestsMyocardial bridges (MB) with associated upfront atherosclerotic lesions are common findings on coronary computed tomography angiography (CTA). Abnormal septal wall motion in exercise echocardiography (EE) may to be associated with MB. Intravascular ultrasound (IVUS) is considered the gold standard for the detection of MB. We investigate whether CTA is comparable to IVUS for the assessment of MB and upstream plaques in symptomatic patients with suspicion for MB raised by EE.
Clinical Associate Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
BioDr. Harmeet Bedi is the Director of Interventional Pulmonology & Bronchoscopy at Stanford University. His expertise is in minimally invasive techniques used in the diagnosis and treatment of various airway and lung diseases such as lung cancer, benign & malignant airway obstruction, and pleural diseases. He specializes in rigid & flexible bronchoscopy, robotic bronchoscopy, airway stent placement, balloon bronchoplasty, endobronchial ultrasound (EBUS), and various pleural procedures. He also specializes in a variety of tumor ablative therapies including laser therapy, electrocautery, argon plasma coagulation (APC), brachytherapy, and cryotherapy.
He founded the cone-beam computed tomography (CBCT) - guided bronchoscopy program at Stanford in 2019. CBCT-guided bronchoscopy is a novel and cutting-edge technique which combines bronchoscopy with CT imaging, allowing for improved localization and diagnosis of peripheral lung nodules. Additionally, CBCT-guided bronchoscopy will allow for numerous potential cancer therapies that are currently under development.
Dr. Bedi is a principal investigator and co-investigator on multiple clinical trials related to bronchoscopy, thoracic imaging, pulmonary nodules, and lung cancer. Specifically, he has multiple research interests within the realm of bronchoscopic device innovation and CBCT-guided bronchoscopy.
Assistant Professor of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsThe focus of my research is to develop novel imaging and treatment strategies to detect and better manage cancer. This approach relies first on the identification and validation of molecular targets and biomarkers that are linked with underlying the underlying biology driving the initiation and progression of cancers. We then develop novel small molecule based radiotracers to monitor fundamental molecular and cellular processes occurring in living subjects using positron emission tomography (PET) with the goal of improving cancer diagnosis and management. We additionally develop novel peptide based theragnostic agents for stratification of patients with high receptor expression, treatment with targeted radionuclide therapy, and subsequent monitoring of treatment response. Our overall goal is to develop multiple clinically translatable strategies to improve cancer diagnosis, management, and outcomes.
Professor of Developmental Biology, of Computer Science, of Pediatrics (Genetics) and of Biomedical Data Science
Current Research and Scholarly Interests1. Automating monogenic patient diagnosis.
2. The genomic signatures of independent divergent and convergent trait evolution in mammals.
3. The logic of human gene regulation.
4. The reasons for sequence ultraconservation.
5. Cryptogenomics to bridge medical silos.
6. Cryptogenetics to debate social injustice.
7. Managing patient risk using machine learning.
8. Understanding the flow of money in the US healthcare system.
Associate Professor of Pathology
Current Research and Scholarly InterestsOur goal is to understand the mechanisms regulating the development of human systems. Drawing on both pluripotent stem cell biology, hematopoiesis, and immunology, combined with novel high-content single-cell analysis (CyTOF – Mass Cytometry) and imagining (MIBI-Multiplexed Ion Beam Imaging) we are creating templates of ‘normal’ human cellular behavior to both discover novel regulatory events and cell populations as well as understand dysfunctional processes such as cancer.
Clinical Associate Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
Current Research and Scholarly InterestsMy research focuses on improving cancer survivorship through better understanding of long-term health outcomes and through the development of theoretically driven, evidence-based behavioral interventions to improve adjustment, risk management, and quality of life. To this end, I lead studies aimed to guide and support patient decision-making and self-management after cancer. Much of my work focuses on the experiences of young adults affected by cancer.
Jonathan S. Berek, MD, MMSc
Laurie Kraus Lacob Professor
BioLaurie Kraus Lacob Professor
Stanford University School of Medicine
Director, Stanford Women’s Cancer Center
Senior Advisor, Stanford Cancer Institute
Executive Director, Stanford Health Communication Initiative
Director, MedArts Films
Stanford Center for Health Education
Shirley R. and Leonard W. Ely, Jr. Professor of the School of Humanities and Sciences
Current Research and Scholarly InterestsWe use genetic, genomic and cell biological approaches to study cell fate acquisition, focusing on cases where cell fate is correlated with asymmetric cell division.
Alfred Woodley Salter and Mabel G. Salter Endowed Professor of Pediatrics
Current Research and Scholarly Interests1. Using iPSC-derived cardiomyocytes to understand hypertrophic cardiomyopathy and heart failure associated with congenital heart disease.
2. Role of alterations in mitochondrial dycamics and function in normal physiology and disease.
3. Differences between R and L ventricular responses to stress,
4. Immune biomarkers of risk after pediatric VAD implantation.
5. Biomarkers for post-transplant lymphoproliferative disorder.
Alice Bertaina MD, PhD
Lorry I. Lokey Professor
Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.
Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology
BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.
Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.
The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.
Allison Betof Warner, MD, PhD
Assistant Professor of Medicine (Oncology)
BioDr. Betof Warner is a board-certified, fellowship-trained medical oncologist with the Cutaneous Oncology Program and an Assistant Professor in the Department of Medicine, Division of Medical Oncology. She also serves as Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program.
Clinical interests of Dr. Betof Warner include treatment of advanced melanoma, immunotherapy, and cellular therapies for solid tumors. She has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy, which is expected to become standard of care for immunotherapy-refractory melanoma.
Dr. Betof Warner serves as the leader of the Melanoma & Cutaneous Oncology Clinical Research Group, with research interests focused on tumor response to immunotherapy. She has been the principal investigator of multiple clinical trials focusing on immunotherapy-refractory melanoma and is internationally recognized for her expertise in central nervous system metastases and the use of novel cellular therapies. Dr. Betof Warner collaborates with investigators around the world in surgery, neuro-oncology, neurosurgery, radiation oncology, and pathology. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.
In addition to publishing her research in peer-reviewed journals, Dr. Betof Warner has served as an editorial and grant reviewer for multiple organizations, including the Melanoma Research Foundation. She has authored book chapters and case reports, contributed to national guidelines, and presented her findings at regional, national, and international meetings.
Dr. Betof Warner is a member of multiple professional organizations and societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer, where she serves on the Early Career Scientist Committee. She is also a member of the American College of Sports Medicine and the European Society for Medical Oncology.
Associate Professor of Medicine (Hematology) and of GeneticsOn Partial Leave from 09/25/2023 To 12/15/2023
Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.
Life Science Research Professional 4, Stanford Cancer Institute Core
BioJing Bian, PhD, LSRP4
B.S. Suzhou University
M. Sc. Nanjing University of Technology
Ph.D. Cleveland Clinic and Cleveland State University
Michael S Binkley, MD, MS
Assistant Professor of Radiation Oncology (Radiation Therapy)
BioDr. Binkley is a radiation oncologist specializing in lymphoma treatment and an assistant professor in the Stanford University School of Medicine Department of Radiation Oncology.
His clinical expertise includes stereotactic ablative radiotherapy (SABR), total lymphoid and total body irradiation, and intensity modulated radiation therapy (IMRT).
For each patient, Dr. Binkley develops a personalized, comprehensive, and compassionate care plan. His goals are to improve both health and quality of life.
Dr. Binkley has conducted extensive research to advance cancer treatment. In his post-doctoral fellowship at Stanford, he studied the use of genomic signatures to predict response to radiotherapy. His current clinical and laboratory research seek to identify prognostic and predictive clinical, radiographic, and genomic factors to inform individualized treatment strategies.
He has co-authored articles on his research discoveries published in Cancer Discovery, Blood, the International Journal of Radiation Oncology*Biology*Physics, and elsewhere. Topics have included innovations in the treatment of lymphoma and lung cancer.
He also has made invited presentations to colleagues at national and international conferences. He has presented the latest findings on radiation therapy for lung cancer and lymphoma at meetings of the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and International Conference on Malignant Lymphoma (ICML).
Honors for Dr. Binkley include the Malcolm A. Bagshaw Award for leadership and outstanding scientific achievement. This award is named for a pioneer in radiation therapy and former chair of the Departments of Radiology and Radiation Oncology at Stanford University School of Medicine.
Dr. Binkley is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Association for Cancer Research. He is a founding member of the Global nLPHL One Working (GLOW) Working Group, an international collaboration studying nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in children and adults.
Associate Professor of Radiology (Pediatric Radiology) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsStudies on apoptotic cell death in vivo using the H MRS phenomenon.
Helen M. Blau
Donald E. and Delia B. Baxter Foundation Professor, Director, Baxter Laboratory for Stem Cell Biology and Professor, by courtesy, of Psychiatry and Behavioral Sciences
Current Research and Scholarly InterestsProf. Helen Blau's research area is regenerative medicine with a focus on stem cells. Her research on nuclear reprogramming and demonstrating the plasticity of cell fate using cell fusion is well known and her laboratory has also pioneered the design of biomaterials to mimic the in vivo microenvironment and direct stem cell fate. Current findings are leading to more efficient iPS generation, cell based therapies by dedifferentiation a la newts, and discovery of novel molecules and therapies.
Douglas W. Blayney
Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsImproving the quality of cancer care at Stanford, in our network of care, and nationally
Nikolas Blevins, MD
Larry and Sharon Malcolmson Professor in the School of Medicine, Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsInner ear microendoscopy -- Developing techniques for minimally-invasive imaging of inner ear microanatomy and neural pysiology. Applications include improved cochlear implant development, inner ear regenerative techniques, inner ear surgery, and auditory physiology.
Microsurgical robotics -- Developing scalable microsurgical instrumentation and robotic techniques for use in head and neck surgery.
Surgical Simulation -- Immersive environment for temporal bone surgical simulation.
Professor (Research) of Biomedical Data Science (BDS), Emeritus
BioI received my PhD. in Mathematical Statistics in 1967. I joined the research community at the Stanford University School of Medicine, Division of Immunology & Rheumatology, in 1984 as head statistician directing the biostatistics consulting and analytic support of the Arthritis Rheumatism Aging Medical Information System (ARAMIS) and Multipurpose Arthritis Center (MAC) grant-related research programs. In 1993 I was appointed Associate Professor with a joint appointment in the Departments of Medicine and of Health Research & Policy, and am currently Professor of Biostatistics at Stanford University, emeritus since 2007. My contributions to the statistics literature span numerous fields, including methods of sample size estimation, efficiency and bias of estimators, research methods for kappa statistics, non-parametric classification methods and methods of assessing multi-parameter endpoints. I have over 200 peer-reviewed publications. I have been directly involved with the development of numerous criteria rules for classification of diseases and with establishing guidelines for clinical trial research and in proposing responder criteria for osteoarthritis drugs. Since 1987, I have been a consultant on an ad hoc basis to pharmaceutical and biotechnical firms, including both start-up and established companies. I have extensive experience with devices, drugs and biologics and have participated in all aspects of applying statistics to implement investigational plans; e.g.: for protocol development, design of trials, database design. I’ve been a member of the FDA Statistical Advisors Panel, the statistical member on numerous data safety monitoring boards, and frequently represent companies at meetings with the FDA
Paul D. Blumenthal, MD, MPH
Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsImproving Access to Family Planning Services in Low Resource Settings:
Through a collaboration with Population Services International, the Stanford Program for International Reproductive Education and Services (SPIRES) provides technical direction in a program designed to improve access to and uptake of family planning, particularly Long Acting Reversible Contraception (LARC) such as IUDs and implants, in 14 developing countries globally. The first year saw insertion of over 280,000 IUDs.
Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems BiologyOn Leave from 03/01/2023 To 12/31/2023
Current Research and Scholarly InterestsOur lab uses chemical, biochemical, and cell biological methods to study protease function in human disease. Projects include:
1) Design and synthesis of novel chemical probes for serine and cysteine hydrolases.
2) Understanding the role of hydrolases in bacterial pathogenesis and the human parasites, Plasmodium falciparum and Toxoplasma gondii.
3) Defining the specific functional roles of proteases during the process of tumorogenesis.
4) In vivo imaging of protease activity
Ph.D. Student in Cancer Biology, admitted Autumn 2021
BioOriginally from State College, Pennsylvania, Sam graduated with honors from Penn State University with a B.S. in Chemistry and a minor in Biology. He subsequently spent three years working at the Lankenau Institute for Medical Research for Dr. Ellen Heber-Katz. Sam hopes to expand the paradigm of cancer research and help to develop novel therapies for cancer and other ailments. He is also interested in optimization of physical and mental performance.
Melissa L Bondy
Stanford Medicine Discovery Professor, Professor of Epidemiology and Population Health and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsPrincipal Investigator, Discovery, Biology and Risk of Inherited Variants in Glioma, 1R01CA217105-01A1, NIH/NCI, 05/01/2018-06/30/2022, MPI (Contact PI)
Principal Investigator, Characterizing Germline and Somatic Alterations by Glioma Subtypes and Clinical Outcome, 1R01CA232754-01, 07/01/2019-06/30/2023, MPI (Contact PI)
Co-Leader (Project), SPORE in Brain Cancer, PI – Fred Lang (Sub with MD Anderson), 2 P50CA127001-11, 09/01/2019-08/31/2023
Co-Investigator, Stanford University Cancer Center, PI – Steve Artandi, P30 CA124435, NCI, 09/15/10-05/31/22
Co-Investigator, Ovarian Cancer Survival in African-American Women, PI, Joellen Schildkraut, R01 CA237318-01A1, NIH/NCI, 07/01/2020-06/31/2025
Donna M. Bouley, DVM, PhD
Professor of Comparative Medicine at the Stanford University Medical Center, Emerita
Current Research and Scholarly InterestsResearch interests: ocular pathology, host-pathogen interactions in infectious disease, infectious disease in frogs, phenotypic characterization of tg and ko mice, histopathology of minimally-invasive radiological ablation techniques (focused ultrasound, cryoablation).
Linda Boxer, MD, PhD
Vice Dean of the School of Medicine and Stanley McCormick Memorial Professor
Current Research and Scholarly InterestsRegulation of expression of oncogenes in normal and malignant hematologic cells.
Scott D. Boyd, MD PhD
Stanford Professor of Food Allergy and Immunology and Professor of Pathology
Current Research and Scholarly InterestsOur goal is to understand the lymphocyte genotype-phenotype relationships in healthy human immunity and in immunological diseases. We apply new technologies and data analysis approaches to this challenge, particularly high-throughput DNA sequencing and single-cell monoclonal antibody generation, in parallel with other functional assays.
Associate Professor of Biochemistry and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsThe Brandman Lab studies how cells sense and respond to stress. We employ an integrated set of techniques including single cell analysis, mathematical modeling, genomics, structural studies, and in vitro assays.
James D. Brooks
Keith and Jan Hurlbut ProfessorOn Leave from 07/01/2023 To 12/31/2023
Current Research and Scholarly InterestsWe use genomic approaches to identify disease biomarkers. We are most interested in translating biomarkers into clinical practice in urological diseases with a particular focus in cancer.
Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsWe seek to understand the mechanisms responsible for the resistance of cancers to treatment and to develop strategies to overcome these resistances. We are using molecular and cellular techniques and mouse models to potentiate the activity of radiation on tumors by inhibiting the bone marrow rescue of the tumor vasculature following therapy.
Wes (Janice) Brown
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Janice (Wes) Brown specializes in the treatment of infectious complications that occur in patients who are receiving cancer treatments or are undergoing transplantation of solid organs or hematopoietic cells. She has been a member of the Blood and Marrow Transplantation faculty for more than twenty years and co-founded the Immunocompromised Host Infectious Diseases consultation service. Dr. Brown’s special interest is to understand the nature of immunodeficiency resulting from an ever- evolving spectrum of targeted and immunomodulatory therapy. Her laboratory studies approaches to enhance and/or rebuild protective immunity. She is a leader in the design and execution of clinical trials of new treatments for infections that have significantly improved the outcomes of high-risk patients.
Michele and Timothy Barakett Endowed Professor
Current Research and Scholarly InterestsOur lab studies the molecular basis of longevity. We are interested in the mechanism of action of known longevity genes, including FOXO and SIRT, in the mammalian nervous system. We are particularly interested in the role of these longevity genes in neural stem cells. We are also discovering novel genes and processes involved in aging using two short-lived model systems, the invertebrate C. elegans and an extremely short-lived vertebrate, the African killifish N. furzeri.
Kelly Bugos MS, ANP-BC, NPD-BC, AOCNP
Affiliate, Central Mgmt-Misc AR
BioKelly Bugos MS, ANP-BC is a Director for the Center for Advanced Practice and a nurse practitioner specializing in cancer survivorship at Stanford Health Care. Ms. Bugos is the Director of Professional Development and the Advanced Practice Provider (APP) Fellowship Program. As director, Ms. Bugos focuses on APP leadership development. Opened in 2016, the APP Fellowship Program educates and trains APPs in transition to professional practice and specialty care, like administration and cancer care. She founded the cancer survivorship clinics at Stanford in 2012 and continues to focus her clinical work on helping people touched by cancer restore their health after treatment. Ms. Bugos has developed other professional roles and programs over her career at Stanford, like the nurse practitioner position in the 1990s. She has expertise in leadership of advanced practice providers, complex patient care in the outpatient setting, long term and late effects of cancer and its treatment, including symptom management. She is a frequent speaker and author on these topics at the regional and national level.
Nam Quoc Bui
Clinical Assistant Professor, Medicine - Oncology
BioDr. Bui is a Clinical Assistant Professor of Medicine at the Stanford Cancer Institute and a specialist in Sarcoma. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data.
His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies. He is involved in numerous sarcoma clinical trials, leading efforts to take new therapeutics from the lab to clinical practice. He also is involved in education at the Stanford University School of Medicine, serving as a lecturer and mentor to students and trainees. Dr. Bui is the founding Editor-in-Chief of the journal “Current Problems in Cancer: Case Reports”, an international, peer-reviewed journal that publishes groundbreaking cases that give insight into redefining concepts in cancer.
Klaus Bensch Professor of Pathology
Current Research and Scholarly InterestsOur interests include:
1) The physiology and function of lymphocyte homing in local and systemic immunity;
2) Biochemical and genetic studies of molecules that direct leukocyte recruitment;
3) Chemotactic mechanisms and receptors in vascular and immune biology;
4) Vascular control of normal and pathologic inflammation and immunity;
5) Systems biology of immune cell trafficking and programming in tumor immunity.
Mark Buyyounouski, MD, MS, FASTRO
Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsPatient-centered and artificial intelligence-augmented medical decision making
Mark A. Cappelli
Professor of Mechanical Engineering
BioProfessor Cappelli received his B.Sc. degree in Physics (McGill, 1980), and M.A.Sc and Ph.D. degrees in Aerospace Sciences (Toronto, 1983, 1987). He joined Stanford University in 1987 and is currently a Professor in the Department of Mechanical Engineering and Co-Director of the Engineering Physics Program. He carries out research in applied plasma physics with applications to a broad range of fields, including space propulsion, aerodynamics, medicine, materials synthesis, and fusion.
Ian Carroll, MD, MS
Associate Professor of Anesthesiology, Perioperative and Pain Medicine (Adult Pain)On Partial Leave from 12/01/2023 To 01/07/2024
Current Research and Scholarly InterestsWe are committed to promoting an understanding of cerebrospinal fluid (CSF) leaks, and ensuring that all patients who are suffering from cerebrospinal fluid leaks receive appropriate diagnosis and treatment of this devastating, chronic, and fixable condition. We believe this can be best accomplished in a multidisciplinary setting involving expertise in radiology, neurology, and interventional pain medicine.
Chris Cartwright, MD
Professor of Medicine (Gastroenterology and Hepatology), Emerita
Current Research and Scholarly InterestsMolecular mechanisms of intestinal cell growth control; function and regulation of the Src family of tyrosine kinases in normal cells, and their deregulation in cancer cells.
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.
Instructor, Pediatrics - Stem Cell Transplantation
BioDr. Cepika is an immunologist with an extensive background in translational research, autoimmunity, autoinflammation, and human systems immunology. Her goal is to understand the mechanisms governing immunological tolerance, and to leverage this knowledge to cure currently incurable diseases.
Dr. Cepika received her MD degree and a PhD in Immunology from the University of Zagreb School of Medicine in Croatia. There, she focused on the immunomonitoring of patients with lupus, identifying how circulating DNA levels changed with therapy. Subsequently, she joined the lab of Dr. Virginia Pascual at the Baylor Institute for Immunology Research in Dallas, Texas. Dr. Pascual had previously discovered that IL-1beta is a key pathogenic player in systemic juvenile idiopathic arthritis (sJIA), but the immune alterations contributing to IL-1beta-mediated inflammation remained unknown. To address this, Dr. Cepika developed a 3D in vitro stimulation assay to evaluate immune responses of blood leukocytes of pediatric sJIA patients. In combination with integrated bioinformatics analysis, this approach identified aberrant cellular responses, transcriptional pathways and genes that shed new light on immune dysregulation in sJIA. This assay (tollgene.org) can be further applied to dissect underlying immunopathogenic mechanisms in many human disorders.
Currently, Dr. Cepika is an Instructor in the Pediatric Division of Stem Cell Biology and Regenerative Medicine at Stanford University School of Medicine. There, she is working to uncover the underlying molecular mechanisms that govern the differentiation and function of antigen-inducible regulatory T cells called type 1 regulatory T (Tr1) cells, and use this knowledge to design Tr1 cell-based therapies to improve the outcomes of patients with cancer, autoimmunity, or receiving allogeneic cell or organ transplants.
Anne Lynn S. Chang, MD
Professor of Dermatology
Current Research and Scholarly InterestsI have two main research interests:
1) to better understand and treat patients with aggressive basal and squamous cell carcinomas
2) to better understand the genetic and epigenetic mechanisms of healthy human skin aging and to translate these insights into better care of skin diseases enriched in older patients particularly skin cancer and rosacea
Howard Y. Chang, MD, PhD
Virginia and D. K. Ludwig Professor of Cancer Research and Professor of Genetics
Current Research and Scholarly InterestsOur research is focused on how the activities of hundreds or even thousands of genes (gene parties) are coordinated to achieve biological meaning. We have pioneered methods to predict, dissect, and control large-scale gene regulatory programs; these methods have provided insights into human development, cancer, and aging.
James K. Chen
Jauch Professor and Professor of Chemical and Systems Biology, of Developmental Biology and of Chemistry
Current Research and Scholarly InterestsOur laboratory combines chemistry and developmental biology to investigate the molecular events that regulate embryonic patterning, tissue regeneration, and tumorigenesis. We are currently using genetic and small-molecule approaches to study the molecular mechanisms of Hedgehog signaling, and we are developing chemical technologies to perturb and observe the genetic programs that underlie vertebrate development.
Michelle M. Chen, MD, MHS
Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)
BioDr. Chen is a fellowship-trained head and neck surgical oncologist with a board certification in otolaryngology and a clinical assistant professor with the Stanford School of Medicine Department of Otolaryngology.
Her practice focuses on the treatment of cancers that affect the head and neck. She has received additional training in microvascular reconstruction and transoral robotic surgery.
Dr. Chen has an active lab involved in head and neck cancer health services research and her work has appeared in numerous journals, including The Journal of the American Medical Association, Cancer, Journal of the National Cancer Institute, and Journal of Clinical Oncology. She has also authored chapters in textbooks on head and neck cancer treatment.
Dr. Chen is a member of the American Academy of Otolaryngology—Head & Neck Surgery (AAOHNS) and the American Head & Neck Society.
Postdoctoral Scholar, Stanford Cancer Center
BioYiyun Chen, Ph.D. is a Postdoctoral Fellow at Professor Crystal Mackall’s group at Stanford Cancer Institute.
Dr. Chen studied biochemistry and structural biology in her undergraduate and master trainings at The Hong Kong University of Science and Technology, where she eventually obtained her Ph.D. degree in computational biology under the supervision of Professor Jiguang Wang. During her Ph.D. training, she has developed her skill sets in analyzing and integrating various types of patient-derived sequencing data, published three first-author and four co-author papers, and received two awards for top postgraduate students. Through interdisciplinary collaborations with cancer biologist and clinicians in US and Asia, her work has uncovered tumor-specific immune cell subtypes and novel noncoding RNAs and generated new insights into precision medicine in glioma, lymphoma and gastric cancer.
Applying her expertise in computational cancer biology and immunology, her current research is focused on identifying molecular mechanisms that contribute to the clinical outcomes of patients undergoing CAR-T immunotherapy. At Mackall Lab, she will contribute to tailoring computational pipelines for profiling the spatiotemporal dynamics of the tumor and immune microenvironment and translate new discoveries into cancer therapeutics.
Alan G. Cheng, MD
Edward C. and Amy H. Sewall Professor in the School of Medicine, Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsActive Wnt signaling maintains somatic stem cells in many organ systems. Using Wnt target genes as markers, we have characterized distinct cell populations with stem cell behavior in the inner ear, an organ thought to be terminally differentiated. Ongoing work focuses on delineating the developing significance of these putative stem/progenitor cells and their behavior after damage.
Member, Stanford Cancer Institute
Current Research and Scholarly InterestsThe use of molecular and molecular cytogenetic methods to identify chromosomal abnormalities in acquired and congenital disorders.
Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsDr. Cheung's research interests focus on liver diseases, with emphasis on viral hepatitis. His past research include investigating the mechanism of viral neutralization of hepatitis B virus at the molecular level and immune response to hepatitis C virus. Dr. Cheung is studing various aspects of hepatitis C, both clinical and translational research.
Director, SUMS, Mass Spectrometry Center
Current Role at StanfordDirector, Stanford University Mass Spectrometry (SUMS) core resource laboratory
Professor of Microbiology & Immunology
Current Research and Scholarly InterestsContribution of T cells to immunocompetence and autoimmunity; how the immune system clears infection, avoids autoimmunity and how infection impacts on the development of immune responses.
Albert Sean Chiou, MD, MBA
Clinical Associate Professor, Dermatology
Current Research and Scholarly InterestsI am a clinical researcher interested in evaluating promising new diagnostic paradigms and treatments for serious or poorly treated, chronic skin conditions. My research currently includes:
- Treatments for itch from epidermolysis bullosa
- Treatments for chronic wounds for patients with recessive dystrophic epidermolysis bullosa (In collaboration with Dr. Jean Tang and Dr. Peter Marinkovich)
- Treatments for atopic dermatitis, psoriasis, and other inflammatory skin conditions
- Artificial intelligence approaches for melanoma and skin cancer early detection
- Imaging mass spectrometry for skin cancer margin analysis and diagnosis
I collaborate with other faculty within the Stanford Skin Innovation and Interventional Research Group (SIIRG) to conduct investigator initiated and sponsored clinical trials seeking to improve care for important dermatologic diseases
Please learn more about our work at: https://siirg.stanford.edu/
Assistant Professor of Chemical and Systems Biology
Current Research and Scholarly InterestsResearch in my laboratory is aimed at understanding how eukaryotes replicate their DNA despite numerous challenges (collectively known as replication stress), and more generally – how eukaryotic cells safeguard genome integrity. Specifically, we are investigating: (i) mechanisms that regulate the activity of the replicative helicase during replication stress, (ii) mechanisms that control the inheritance of epigenetic information during replication, and (iii) mechanisms of ubiquitin-mediated regulation of genome maintenance. We utilize single-molecule microscopy to directly image fluorescently-labeled replication factors and track them in real time in Xenopus egg extracts. I developed this system as a postdoctoral fellow, and used it to monitor how the eukaryotic replicative helicase copes with DNA damage. We plan to further extend the capabilities of this platform to directly visualize other essential replication factors, nucleosomes, and regulatory post-translational modifications like ubiquitin chains. By elucidating molecular mechanisms responsible for maintaining genome stability, we aim to better understand the link between genome instability and cancer, and how these mechanisms can be harnessed to improve disease treatment.
Associate Professor of Surgery (Pediatric Surgery)
BioDr. Chiu obtained his B.S. degree in Biological Sciences and graduated with Honors from Stanford University. After graduating, he received his Medical Degree at Northwestern University Feinberg School of Medicine, where he remained for his internship and General Surgery residency training. Dr. Chiu completed his Pediatric Surgery training at The Children’s Hospital of Philadelphia. He is an Associate Professor at Stanford University School of Medicine where he has an active research program studying innovative approaches to treat patients with neuroblastoma.
Current Research and Scholarly InterestsMy major research interests include cancer epidemiology with a concentration in early detection and screening for cancer. My current research focuses on second malignancies among cancer survivors with special interests in causal inference from real-world observational data sources, dynamic risk predictive modeling, and simulation models of cancer control interventions on their effects on population trends in incidence and mortality. My research involves the application of competing-risk and high-dimensional data analysis using large population-based prospective cohorts, clinical trial data, electronic health records extracted through the data mining process, and cancer genomics data.
Professor of Medicine (Oncology) and of Biochemistry
Current Research and Scholarly InterestsAfter shuttering the wet lab, we have focused on: a point-of-care device to measure blood ammonia and prevent brain damage; a human protein complex that juxtaposes and joins DNA ends for repair and V(D)J recombination; and strategies for teaching students and for reducing selection bias in educational programs.